Abstract

Cancer genetic heterogeneity offers a wide repertoire of molecular determinants to be screened as therapeutic targets. Here, we identify potential anticancer targets by exploiting negative genetic interactions between genes with driver loss-of-function mutations (recessive cancer genes) and their functionally redundant paralogs. We identify recessive genes with additional copies and experimentally test our predictions on three paralogous pairs. We confirm digenic negative interactions between two cancer genes (SMARCA4 and CDH1) and their corresponding paralogs (SMARCA2 and CDH3). Furthermore, we identify a trigenic negative interaction between the cancer gene DNMT3A, its functional paralog DNMT3B, and a third gene, DNMT1, which encodes the only other human DNA-methylase domain. Although our study does not exclude other causes of synthetic lethality, it suggests that functionally redundant paralogs of cancer genes could be targets in anticancer therapy.
Original languageEnglish
Article numberN/A
Pages (from-to)1519-1526
Number of pages8
JournalCell Reports
Volume5
Issue number6
DOIs
Publication statusPublished - 26 Dec 2013

Fingerprint

Dive into the research topics of 'Recessive cancer genes engage in negative genetic interactions with their functional paralogs'. Together they form a unique fingerprint.

Cite this